Adial Pharmaceuticals Inc ADIL.OQ ADIL.O is expected to show no change in quarterly revenue when it reports results on March 2 (estimated) for the period ending December 31 2025
LSEG's mean analyst estimate for Adial Pharmaceuticals Inc is for a loss of $2.15 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Adial Pharmaceuticals Inc is $20.00, about 690.5% above its last closing price of $2.53
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -3.91 | -3.50 | -2.00 | Beat | 42.9 |
Jun. 30 2025 | -5.50 | -6.25 | -4.50 | Beat | 28 |
Mar. 31 2025 | -11.26 | -12.37 | -8.50 | Beat | 31.3 |
Dec. 31 2024 | -9.37 | -9.50 | -8.75 | Beat | 7.9 |
Sep. 30 2024 | -11.59 | -11.00 | -9.50 | Beat | 13.6 |
Jun. 30 2024 | -13.35 | -13.37 | -14.75 | Missed | -10.3 |
Mar. 31 2024 | -8.25 | -8.25 | -15.50 | Missed | -87.9 |
Dec. 31 2023 | -22.25 | -19.00 | -33.75 | Missed | -77.6 |
This summary was machine generated February 27 at 13:49 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments